SMA stem-cell 'success' claims are scarce due to minimal data. The few case series describe 'stabilisation' in individual children; no controlled trial has set a consensus rate. Approved therapies (nusinersen, gene therapy) show proven motor and survival benefit in controlled trials; stem cells are not proven to match them. Any benefit, if real, would be slowing of decline — evidence is insufficient for strong claims.
Five registered trials and 1 recruiting study address stem-cell therapy in SMA — the smallest landscape among the conditions here. Published data are sparse and largely single-centre observational. Some describe stabilisation or slowed decline over 6–12 months; others minimal change. SMA's rapid natural progression makes any stability potentially notable, but separating stem-cell effects from approved disease-modifying therapies (nusinersen, gene therapy) is difficult without controls. No trial has reversed motor-neuron loss.
Съм ли кандидат? → · Spinal Muscular Atrophy: full overview → · Цена Гръбначна мускулна атрофия → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка